Ignite Creation Date:
2024-05-06 @ 7:10 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02480088
Status:
COMPLETED
Last Update Posted:
2017-10-27
First Post:
2015-06-17
Brief Title:
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery Association With ABCB1 Polymorphism
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Opioid-based intravenous patient-controlled analgesia IV-PCA offers excellent pain control however its use inevitably increases the incidence of postoperative nausea and vomiting PONV Ramosetron and palonosetron are commonly used 5-HT3 antagonists for the prevention and treatment of PONV It is not clear which one has superior antiemetic efficacy for the prevention of PONV in patients using opioid-based IV-PCA The antiemetic efficacy of 5HT3 antagonists may be influenced by polymorphism of ABCB1 a drug-transporter gene This study evaluates relative antiemetic efficacy of ramosetron and palonosetron in patients using IV-PCA after spinal surgery and impact of ABCB1 polymorphism on the antiemetic efficacy of the ramosetron and palonosetron The incidence and intensity of PONV during postoperative 48 h will be assessed ABCB1 polymorphisms 3435CT and 2677GTA will be evaluated in all patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None